CDMO cell and gene therapy selection: capacity, slots and technology transfer

The questions that separate providers

1. Experience in your modality specifically. Viral vector production, autologous cell processing, allogeneic manufacture and gene-edited products are different operations with different equipment and different problems. Ask how many programmes in your exact modality the site has run, and ask to speak to one of those sponsors.
2. Suite capacity and what a slot means. Capacity is measured in suites and in the changeover between campaigns, and for autologous products in slots per period. Establish what is contractually reserved, what happens if your timeline slips, and what happens if theirs does.
3. Starting material logistics. Where the starting material is a patient's cells, the chain of identity and the chain of custody from collection to manufacture and back are part of the service. Ask how these are managed, what the systems are, and what happens when a shipment is delayed.
4. Analytics and potency. Potency assays for these products are frequently the hardest part of the programme and are less standardised than for conventional biologics. Establish who develops them, who owns them, and how they transfer, because this is where timelines slip most often.
5. Regulatory experience and inspection history. Ask which authorities have inspected the site, when, for which modality, and how the site supported previous sponsors' filings. Experience of the regulatory path in your modality is worth more than nominal capacity.

Technology transfer is the highest risk stage with a CGT CDMO

Processes in this field are frequently less defined than in conventional biologics, and more of the knowledge sits in people rather than in documents. Ask how transfer is run, who leads it, how long it takes and how comparability is demonstrated at the receiving site.

Budget for the transfer to reveal process gaps. Where it does, finding them at the receiving site is the expected outcome rather than a failure, and a provider that plans for it is a better partner than one that does not.

What to settle in a CGT manufacturing contract

Ownership of the process, the analytical methods and any improvement; what happens when a batch fails and who pays; the consequences of slot slippage on both sides; and the position on materials and licences embedded in the process.

For autologous products, also settle the failure case for an individual patient batch, because the consequences there are not only commercial.

biologics cmc and what the package contains

biologics cmc is the chemistry, manufacturing and controls record: the cell line and its history, the process and its ranges, the analytical methods and their validation, the specification and the stability that supports it. It is assembled through development rather than written at the end, which is what makes the early decisions expensive to revisit.

atmp manufacturing and where it differs

atmp manufacturing handles a living product with a short shelf life and often one batch per patient, so release testing has to finish inside the clock and the chain of identity is part of the process rather than a record about it. Comparability after any change is the hardest part, because the product cannot be characterised the way a molecule can.

cell therapy solutions, and what the phrase covers

cell therapy solutions spans the apheresis and logistics at the start, the engineering and expansion in the middle and the cryopreservation and release at the end, and a provider rarely covers all of it. The join between the parts is where a programme loses time, so the interfaces are what a supply agreement has to name.

Common questions

How do I choose a cell and gene therapy CDMO?

On experience in your exact modality, on real suite capacity and what a reserved slot contractually means, on starting material logistics, and on analytical capability. Price is rarely the deciding factor in this field.

Why are analytics such a problem here?

Potency assays for cell and gene therapy products are less standardised than for conventional biologics and are frequently the hardest part of a programme. Establish who develops them, who owns them and how they transfer.

What makes technology transfer risky in cell and gene therapy manufacturing?

Processes are often less defined and more of the knowledge sits with people rather than in documents, so transfer commonly reveals gaps. A provider that plans for that is a better partner than one that assumes a clean handover.

What does a manufacturing slot actually guarantee?

Only what the contract says. Establish what is reserved, what happens if your timeline slips and what happens if the provider's does, because capacity in this field is genuinely constrained.

Browse by service class

• Compare Gene synthesis on advertised prices